KB803 + Placebo
Phase 3Recruiting 0 views this week 0 watching⚡ Active
Interest: 44/100
44
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Dystrophic Epidermolysis Bullosa
Conditions
Dystrophic Epidermolysis Bullosa, DEB - Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, Dominant Dystrophic Epidermolysis Bullosa
Trial Timeline
Jun 20, 2025 → Dec 1, 2026
NCT ID
NCT07016750About KB803 + Placebo
KB803 + Placebo is a phase 3 stage product being developed by Krystal Biotech for Dystrophic Epidermolysis Bullosa. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07016750. Target conditions include Dystrophic Epidermolysis Bullosa, DEB - Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa.
What happened to similar drugs?
0 of 2 similar drugs in Dystrophic Epidermolysis Bullosa were approved
Approved (0) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
17
Activity
15
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07016750 | Phase 3 | Recruiting |
Competing Products
4 competing products in Dystrophic Epidermolysis Bullosa
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Topical beremagene geperpavec + Placebo gel | Krystal Biotech | Phase 1/2 | 29 |
| Topical Beremagene Geperpavec | Krystal Biotech | Phase 3 | 37 |
| Open Label Topical Beremagene Geperpavec (B-VEC) | Krystal Biotech | Phase 3 | 37 |
| LZRSE-Col7A1 Engineered Autologous Epidermal Sheets | Abeona Therapeutics | Phase 1/2 | 22 |